This chapter discusses molecular determinants in pulmonary hypertension. Role of PDE5 Cyclic Nucleotide Phosphodiesterases in Health and Disease provides an integrated volume covering PDE biology from genes to organisms. It examines phosphodiesterases as pharmacological targets as well as the development of specific PDE inhibitors as therapeutic agents. With contributions from pioneers in the field, individual chapters describe one of the 11 known mammalian PDE families including the molecular characteristics, structure, function, and traits unique to each
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
Chronic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibit...
Pulmonary Hypertension is a severe lung disease, which is characterized by vasoconstriction and remo...
This chapter discusses molecular determinants in pulmonary hypertension. Role of PDE5 Cyclic Nucleot...
inhibitors in the management of pulmonary vascular diseases Ghazwan Butrous1,2,* Phosphodiesterase i...
Phosphodiesterases (PDE) are a class of proteins whose most relevant biological activity concerns th...
1. Chronic hypoxic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased c...
Background—Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmon...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Phosphodiesterase 5 (PDE5) is one of the most well-studied phosphodiesterases (PDEs) that specifical...
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate...
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vasc...
Phosphodiesterases (PDEs) are the enzymes to degrade the intracellular second messengers cAMP and cG...
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pu...
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze th...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
Chronic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibit...
Pulmonary Hypertension is a severe lung disease, which is characterized by vasoconstriction and remo...
This chapter discusses molecular determinants in pulmonary hypertension. Role of PDE5 Cyclic Nucleot...
inhibitors in the management of pulmonary vascular diseases Ghazwan Butrous1,2,* Phosphodiesterase i...
Phosphodiesterases (PDE) are a class of proteins whose most relevant biological activity concerns th...
1. Chronic hypoxic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased c...
Background—Phosphodiesterase type 5 (PDE5) is a novel therapeutic target for the treatment of pulmon...
The pathology of pulmonary arterial hypertension (PAH) is characterized by vascular vasoconstriction...
Phosphodiesterase 5 (PDE5) is one of the most well-studied phosphodiesterases (PDEs) that specifical...
By catalyzing hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate...
Phosphodiesterase (PDE) 5 inhibitors reduce cyclic guanylate monophosphate breakdown, promoting vasc...
Phosphodiesterases (PDEs) are the enzymes to degrade the intracellular second messengers cAMP and cG...
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disorder characterized by increased pu...
Cyclic nucleotide phosphodiesterases (PDEs) are known as a super-family of enzymes which catalyze th...
AbstractPulmonary hypertension (PH) is a disease of various origins. Nitric oxide—a potent vasodilat...
Chronic treatment of rats (to induce pulmonary hypertension, PHT) for 14 days increased cGMP-inhibit...
Pulmonary Hypertension is a severe lung disease, which is characterized by vasoconstriction and remo...